IMPORTANCE A substantial number of patients with bullous pemphigoid do not develop skin blisters and may not have received the correct diagnosis. Diagnostic criteria and an optimal diagnostic strategy are needed for early recognition and trials.
M ore than 20% of patients with bullous pemphigoid do not present with typical skin blistering, but with a pruritic nonbullous variant consisting of erythematous urticarial plaques, eczematous lesions, papules and nodules, or only excoriations. [1] [2] [3] These patients with nonbullous pemphigoid may often have a misdiagnosis or be overlooked with a prolonged physician delay, especially in cases in which blisters never develop. 3, 4 Bullous pemphigoid is the most frequent subepidermal autoimmune bullous disease (sAIBD) and mainly affects older people. 1, 5 It is characterized by the presence of circulating IgG autoantibodies targeting the structural proteins BP180 and BP230 of the epidermal basement membrane zone. 5 Annual incidence of bullous pemphigoid in Europe has increased substantially in the past decades, which might be attributed to an aging population, the availability of better diagnostic tests, and the recognition of patients with atypical clinical features. 1, 6 Minimal diagnostic criteria for pemphigoid are needed but have not yet been established. 4, 7 Currently, the diagnosis is based on the typical presentation using combined clinical criteria 8, 9 to separate it from other pemphigoid diseases (such as mucous membrane pemphigoid, linear IgA disease, and epidermolysis bullosa acquisita), the histopathologic features of a subepidermal blister, and the detection of autoantibodies in a skin biopsy specimen by direct immunofluorescence (DIF) microscopy and in a blood sample by various immunoserologic tests. [10] [11] [12] The 2015 European Dermatology Forum consensus recommendations 11 require a positive DIF biopsy result for diagnosis, whereas the 2015 German guideline also allows diagnosis using various combinations of serologic tests. 12 Studies suggest high diagnostic accuracies of commercially available enzyme-linked immunosorbent assay (ELISA) kits, 13,14 but methodologic flaws may have led to an overestimation of the diagnostic accuracy in the intended population. We evaluated the diagnostic accuracy of the DIF test on a skin biopsy specimen and various serologic tests in a paired study design involving a large cohort with suspected bullous or nonbullous pemphigoid. We then assessed the optimal diagnostic strategy by comparing the additional diagnostic value of combined diagnostic tests in multivariable logistic regression modeling, and we evaluated which tests should be performed for diagnosis at least (minimal requirements). Informed by these evaluations, we propose minimal diagnostic criteria for pemphigoid that support early recognition of this common cutaneous autoimmune disease.
Methods

Study Design and Participants
This single-center retrospective study was performed at the Groningen Center for Blistering Diseases, the national referral center for autoimmune bullous diseases in Groningen, the Netherlands. The study population consisted of consecutive patients with suspected pemphigoid from secondary and tertiary care hospitals throughout the Netherlands, including older people who had severe or refractory itch with or without skin blistering. Eligible participants were patients with paired data on at least (1) a skin biopsy specimen for the DIF test; (2) indirect immunofluorescence on a human salt-split skin (IIF SSS) substrate test; and (3) 1 or more routine immunoserologic tests administered between January 1, 2002, and May 1, 2015. Samples were taken at the time of first diagnosis, before introduction of immunosuppressive therapy, and within an inclusion window of a maximum of 4 weeks. This study reports diagnostic tests in accordance with the Standards for Reporting Diagnostic Accuracy; see the eAppendix in the Supplement for a list of essential items for reporting diagnostic accuracy studies. 15 According to national regulations in the Netherlands, 16 this type of retrospective noninterventional study with leftover materials for diagnostic purposes does not require approval from the local medical ethical committee.
Reference Standard and Index Tests
No consensus reference standard for the diagnosis of pemphigoid was established. We used as a composite reference standard the criteria for diagnosis of the 2015 German S2k Guideline for diagnosis of bullous pemphigoid. 12 Compatible clinical presentation of pemphigoid was defined as the presence of pruritus and predominant tense skin blisters or nonbullous skin morphologic features (not further specified).
Results of direct immunofluorescence on a skin biopsy specimen were considered positive when linear or linear n-serratedpattern deposits of IgG and/or C3c along the epidermal basement membrane zone were observed. 11, 17 The finding of indirect immunofluorescence on a human salt-split skin substrate (IIF SSS) test was considered positive when epidermal side staining of IgG was observed. 11 The clinical diagnosis of pemphigoid was made in the following cases: (1) compatible clinical presentation and a positive DIF finding, (2) compatible clinical presentation and a positive DIF finding as well as a positive IIF SSS result, (3) compatible clinical presentation and a positive IIF SSS finding as well as positivity in at least 1 other immunoserologic test (eg, immunoblot with reactivity to BP180 or BP230, IIF on monkey esophagus [ME] substrate, or BP180 or BP230 ELISA), and (4) compatible clinical presentation of tense blisters and a compatible histopathologic finding of subepidermal blister as well as a positive BP180 ELISA result and positivity in at least 1 other immunoserologic test (eg, immunoblot with reactivity to BP180 or BP230, IIF ME substrate, or BP230 ELISA). Clinical features and test outcomes of cases with indeterminate or a single positive index test result were discussed among us, specifically by physicians (J.M.M. and M.F.J.), a pathologist (G.D.), and a biochemist (H.P.), to confirm a reject diagnosis of pemphigoid. Histopathologic data were not routinely analyzed in the study because histopathologic study is often nonspecific in nonbullous pemphigoid, does not enable differentiation of subtypes of pemphigoid diseases, and was not available in all cases. 11 Excluded were participants with suspected mucous membrane pemphigoid as well as participants with a diagnosis of other autoimmune (bullous) diseases based on DIF findings and immunoserology results, including a linear u-serrated pattern (epidermolysis bullosa acquisita/bullous systemic lupus erythematosus), solely IgA depositions, or with IgG against autoantigens other than BP180 or BP230 ( Figure 1) . Diagnostic tests and assessments of the reference standard were separately performed. Biopsy specimens for DIF were transported and stored mainly in saline solution (0.9% NaCl, overnight), liquid nitrogen, or Michel medium.
17,18 Biopsy sites were defined in advance as (1) perilesional skin: erythematous nonbullous skin within 2 cm from a lesion; (2) lesional skin: bullous or nonbullous lesion except erosions; and (3) healthy skin: normal-appearing noninflamed skin from the inner aspect of upper arm. Serration pattern analysis was assessed by routine DIF from 2009 onward using either a microscope with a 40× dry objective and 10× ocular lens, with a total magnification of ×400 (Leica DM2000 or LEICA DMRA; Leica Microsystems 
Direct Immunofluorescence
The sensitivity of the index DIF test on a skin biopsy specimen (n = 303) was 88.3% (95% CI, 84.5%-91.3%), and the specificity was 99.2% (95% CI, 98.3%-99.7%). Solitary positive or inconclusive DIF findings were classified as false-positive in 6 participants (0.5%) in whom diagnosis of pemphigoid could not be confirmed, including chronic ulcers and a case of vasculitis. Twenty-one biopsy specimens for DIF contained artifacts with uninterpretable results and were excluded. Comparison of the biopsy sites for DIF of 1482 skin biopsy specimens showed that DIF on perilesional skin was most sensitive (90.4%; 95% CI, 85.7%-93.9%) and was superior to healthy skin (80.7%; 95% CI, 73.5%-86.5%; P = .005) or lesional skin (76.2%; 95% CI, 65.7%-84.8%; P = .002) ( Table 2 ). In the subgroup of participants without skin blisters (n = 788), DIF had a lower sensitivity of 81.1% (95% CI, 70.0%-88.9%), and no statistically significant differences were seen between biopsy sites ( 
Immunoserology
The sensitivity of the index IIF SSS test (n = 263) was 77.0% (95% CI, 72.2%-81.1%), and the specificity was 99.9% (95% CI, Figure 2 ). Positive findings in IIF SSS were always confirmed by positivity in other serologic tests of different methodology ( Figure 2 ). Table 1) . Single false-positive test results of BP180 NC16A were seen in 57 nonpemphigoid controls (11.3%) and of BP230 in 31 controls (7.2%), which included cases with toxic epidermal necrolysis, burns, psoriasis, and atopic dermatitis. In patients with pemphigoid, ELISA detected mean (SD) serum concentrations of anti-BP180 NC16A of 48.8 (50.4) U/mL (eFigure 3 in the Supplement) and anti-BP230 IgG autoantibodies of 25.6 (35.0) U/mL (eFigure 5 in the Supplement) compared with 2.4 (9.3; range, 0-115 U/mL) U/mL and 1.5 (5.3; range, 0-50) U/mL in controls. Performance of combined ELISAs BP180 NC16A and BP230 had a sensitivity of 79.0% (95% CI, 74.4%-82.9%) at the cost of a lower specificity of 83.6% (95% CI, 79.8%-86.8%). Intending to use BP180 NC16A and BP230 in initial diagnosis and to prevent the high number of false- positives, we calculated the positivity cutoff values using receiver operating characteristic curve analysis (eFigures 2 and 4intheSupplement) and specificity comparable to that of DIF and IIF SSS tests (98%). Hence, the positivity cutoff for BP180 NC16A was 30 U/mL, with a corresponding sensitivity of 49.7%, whereas the cutoff for BP230 was set at 15 U/mL, with corresponding sensitivity of 38.8%.
Diagnostic Strategy by Multivariable Logistic Regression Analysis
Presence of skin blisters was the highest predictive factor in the diagnosis of pemphigoid (univariate OR, 7.7; 95% CI, 5.7-10.5). Categorical 5-year age groups (ranging from <49 to >90 years) showed an incremental association with pemphigoid at age greater than 60 years (OR range, 
Bullous vs Nonbullous Pemphigoid
In a subgroup analysis of patients with bullous or nonbullous pemphigoid, a positive DIF finding was observed (213 of 239 cases [89.1%] vs 60 of 74 cases [81.1%]; P = .07). A statistically significant lower frequency of C3c depositions was observed in patients with nonbullous pemphigoid compared with those with bullous pemphigoid (52% vs 77%; P < .001), but no difference in IgG or IgA was found. Positive IIF SSS results were seen in 182 of 239 patients (76.2%) with bullous pemphigoid and 52 of 74 patients (70.3%) with nonbullous pemphigoid (P = .31). Sensitivity and specificity of combined DIF and IIF SSS tests did not differ between patients with bullous or nonbullous pemphigoid (Table 1 ). In contrast, for combined DIF test and BP180 NC16A ELISA, lower specificity, positive predictive value, and diagnostic OR were seen in patients with nonbullous pemphigoid ( Table 1 ), indicating that false-positivity in BP180 NC16A ELISA was more commonly observed in patients with the nonbullous variant than in other participants. Presence of circulating BP180 antibodies was associated with a bullous phenotype (80.3%; univariate OR, 2.6; 95% CI, 1.5-4.6; P < .001). In patients with nonbullous pemphigoid, single reactivity against BP230 was seen more often along with absence of serum autoantibodies against BP180 (18%; P < .001) (eFigure 6 in the Supplement). The mean (SD) serum concentration of anti-BP180 NC16A IgG detected by ELISA was statistically significantly lower in patients with nonbullous pemphigoid compared with patients with bullous pemphigoid (27.7 [34.9] U/mL vs 53.9 [52.9] U/mL; P < .001), whereas serum concentrations of anti-BP230 IgG were similar in both groups. Furthermore, the sole presence of BP230 autoantibodies was associated with a negative skin biopsy result for DIF (10.2%; univariate OR, 5.5; 95% CI, 2.7-11.3; P < .001), whereas the sole presence of BP180 autoantibodies was associated with a positive DIF result (69.7%; univariate OR, 2.5; 95% CI, 1.2-4.9; P = .01).
Discussion
These findings indicate that at least both DIF on a skin biopsy specimen and the IIF SSS serologic test should be performed for the optimal detection of 98.8% of pemphigoid cases. Although positive epidermal staining of IgG by IIF SSS is highly specific and confirmative for pemphigoid diagnosis, it is not sufficient to exclude pemphigoid because of its low sensitivity (77%). In contrast, performing the widely used BP180 NC16A ELISA had no additional value for initial diagnosis in our cohort and showed a high number of false-positives.
Sár dyetal 13 reported similar findings in a retrospective comparative study, with sensitivities of 90% (DIF) and 73% (IF SSS) and specificities of 98% (DIF) and 100% (IF SSS), although these rates were hampered by a high number of missing serologic test data. The higher frequency of IgG (91%), compared with C3c (74%), positivity by DIF in our study can be explained by the saline incubation of most biopsy specimens, which lowers the high dermal background staining of IgG. 18 Sensitivity of the DIF was lower in patients with nonbullous pemphigoid, whereas similar sensitivities were found for IIF SSS in patients with bullous and nonbullous pemphigoid. The high specificity of IIF SSS has been reported many times. 13, [21] [22] [23] [24] The diagnostic test accuracy of IIF ME was congruent with other studies and highly specific, but it had a low sensitivity of 57% and was inferior to IIF SSS. 13 Sensitivity of IIF might have been raised when IgG was specifically stained by a mixture of subclass specific antibodies (eg, IgG1, IgG4). Our results indicated that patients with nonbullous pemphigoid more often have BP230 as a target antigen and lower serum titers of autoantibodies against the immunodominant BP180 compared with patients with bullous pemphigoid. Patients with antibodies against BP230 often had significantly more negative DIF results, and the antibodies against BP230 contributed mainly to IIF positivity. 13, 20, 24 A hypothesis is that antibodies against BP230 bind less to the intracellular target antigen in vivo in a skin biopsy specimen, but they bind to tissue sections of salt-split skin in vitro in which the BP230 antigen is exposed.
21,26
A meta-analysis of the BP180 NC16A ELISA (both commercial and in-house made) analyzed 17 studies with 538 patients with bullous pemphigoid and reported a pooled sensitivity of 87% and specificity of 98%, with the authors concluding that ELISA can be used as a diagnostic screening test in patients with autoimmune bullous diseases.
14 In contrast, we report a low diagnostic performance for ELISA, which is in line with several reports by other investigators. The available clinical criteria for bullous pemphigoid are not applicable in patients with the nonbullous variant. 8, 9 Although histopathologic examination of a lesional skin biopsy specimen of a blister can support the diagnosis of bullous pemphigoid, it is neither sufficient nor essential for diagnosis and cannot distinguish between other subtypes of sAIBD.
12,31 Moreover, histopathologic study is often nonspecific in nonbullous pemphigoid and indistinguishable from other inflammatory dermatoses. 3 These findings suggest that at least both DIF and IIF SSS tests should be performed for the diagnosis of pemphigoid. Subsequently, the minimal diagnostic criteria we propose for pemphigoid diagnosis consist of at least 2 positive results out of 3 criteria (2-out-of-3 rule): (1) pruritus and/or predominant cutaneous blisters, (2) linear IgG and/or C3c deposits (in an n-serrated pattern) by DIF on a skin biopsy specimen, and (3) positive epidermal side staining by IIF SSS on a serum sample. The minimal diagnostic criteria thus contradict that presence of blisters or a histopathologic finding is a prerequisite for diagnosing pemphigoid. To distinguish pemphigoid from other sAIBD, the predominance of cutaneous lesions opposes mucous membrane pemphigoid. The finding of a positive result DIF with linear IgG depositions with undetermined serration pattern along the basement membrane zone does not always imply a definitive diagnosis of pemphigoid. The required performance of an IIF SSS test excludes the subtypes of sAIBD with dermal side binding of autoantibodies: anti-p200 or laminin γ1 pemphigoid, epidermolysis bullosa acquisita or bullous systemic lupus erythematosus, and anti-laminin-332 mucous membrane pemphigoid. Linear IgA disease is excluded by the sole detection of the autoantibodies of IgA isotype and pemphigoid gestationis by the distinct patient population. Subtyping in seronegative patients requires routine DIF serration-pattern analysis to identify the n-serrated pattern in pemphigoid, as opposed to the linear u-serrated pattern in epidermolysis bullosa acquisita.
17
The nosologic entity bullous pemphigoid, postulated 65 years ago by Lever, 32 was adapted to simply pemphigoid in the United Kingdom to avoid redundancy. 33 Therefore, we advocate the use of pemphigoid to encompass both the bullous and nonbullous variants of this cutaneous autoimmune disease that typically presents as a pruritic dermatosis in older people, with or without skin blistering.
Limitations
The limitation of this study is the absence of diagnostic criteria as a reference standard for the diagnosis of pemphigoid. A limitation of all studies of diagnostic accuracy is the inability to incorporate the results of analyzed tests.
Conclusions
We propose minimal diagnostic criteria that encompass the complete clinical spectrum of pemphigoid. These criteria also differentiate pemphigoid from other sAIBD. 
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LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS
BMZ
Intervention: not applicable.
Main study parameters/endpoints: primary study parameters of diagnostic accuracy are the binary classified outcomes of index tests DIF microscopy, IIF SSS, IIF MO and of immunoblot, and the continuous titers of ELISA assays with a positivity cut-off of ≥9 U/ml.
Secondary study parameters are standardized biopsy sites for DIF biopsies, and area under the curve of ROC curve analysis of multivariate models with 95% CIs.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: not applicable in this retrospective cross-sectional study with biobank materials and registry database.
INTRODUCTION AND RATIONALE
Pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly above 70 years old, the disease is associated with a significant morbidity and a one-year mortality up to 6 times higher than age-matched controls. In this study, we aim to investigate the diagnostic accuracy of various available immunopathological and serological laboratory test for diagnosis of pemphigoid, in a large cohort with patients with both bullous and nonbullous clinical features. Furthermore, this study aims to assess the additional diagnostic value of indirect IF on salt-split skin, the optimal diagnostic strategy and minimal diagnostic criteria for pemphigoid.
OBJECTIVES
Primary Objective: to assess the diagnostic accuracy of routine diagnostic tests DIF microscopy, indirect immunofluorescence, immunoblot and ELISA, and to determine the additional value of indirect immunofluorescence on salt-split skin for diagnosis of pemphigoid.
Secondary Objective(s):
 To assess differences in biopsy sites for diagnostic accuracy of DIF microscopy.
 To determine the diagnostic accuracy of DIF microscopy in subjects with nonbullous clinical features.
 To determine the optimal diagnostic strategy for diagnosis of pemphigoid.
 To compose minimal diagnostic criteria of pemphigoid.
STUDY DESIGN
This study is designed as a retrospective, single-center cross-sectional study at the national referral centre for Autoimmune Bullous Diseases in The Netherlands (Department of Dermatology, University Medical Center Groningen). Assessment of all laboratory tests was conducted at the Immunodermatology Laboratory of the department of Dermatology.
Reference standard and study criteria
This study is in accordance with the Standards for Reporting Diagnostic Accuracy. 
Serological assays
The routine multi-step serological laboratory test procedure for subjects with suspected 
STATISTICAL ANALYSIS
Primary study parameter(s)
Single test diagnostic accuracy of binary classified index tests DIF microscopy and IIF SSS and the serological assays is based on the composite reference standard. For each comparison 2x2 contingency tables will be used to present and calculate sensitivities, specificities, positive and negative predictive values, positive and negative likelihood ratios and diagnostic odds ratio, with 95% confidence intervals (95% CIs). Sensitivities and specificities of diagnostic test will be compared head-to-head using McNemar test.
Diagnostic odds ratio represents the odds of each test to correctly detect presence or absence of the target condition and quantify the ability to predict diagnosis of the target condition.
The added diagnostic value of IIF SSS and the optimal diagnostic strategy for diagnosis of pemphigoid will be asses by receiver operator curve (ROC) analysis. The AUC and 
Secondary study parameter(s)
To assess differences in biopsy sites for diagnostic accuracy of DIF microscopy, groups of lesional, perilesional and healthy skin biopsies will be compared using Chi-square test or Fisher's Exact test when variables contain low numbers. To assess differences in biopsy sites for diagnostic accuracy of DIF microscopy in subjects with nonbullous clinical features, lesional, perilesional and healthy skin biopsies will be compared using Chisquare test or Fisher's Exact test when variables contain low numbers.
Other study parameters
Demographic variables will be summarized using descriptive statistics. Mann-Whitney U test and Chi-square test (or Fisher's exact test when variables contain low numbers) will be used to compare medians and proportions. All p-values are two-sided and a p-value <0.05 will be considered statistically significant. Statistical analysis will be performed using SPSS version 22 (SPSS Inc., Chicago, IL, USA).
ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION
Handling and storage of data and documents
The UMCG ACLAB registry includes standardized data on clinical features, transport medium, duration of transport, standardized biopsy sites, differential diagnosis at first presentation, results of immunofluorescence and immunoserology, differential diagnosis based on immunofluorescence, dates and biobank codes. Biobank materials are coded and stored at -80 °C. The UMCG ACLAB registry is built in Microsoft Access and continuously quality checked by database managers. Query criteria are based on the study inclusion and exclusion criteria (4.2 and 4.3) and exported to SPSS and processed.
Data will be handled confidentially. Data will be saved for 15 years after completion of this study. saved in accordance with the Dutch Personal Data Protection Act. This study is designed honouring the CCMO statement on publication policy. This is an investigator initiated study. The results of the study will be made public unreservedly; they will be offered for publication in a peer reviewed journal. In a publication all data will be handled anonymously. Preparation human salt split skin substrate
Aim
To prepare a human skin substrate for detection and localization of specific autoantibodies in patient serum against skin proteins along the epidermal basement membrane zone.
Rationale
Biopsies of healthy human skin will be incubated in saline solution until artificial splitting between dermis and epidermis is achieved. The artificial split will reproducibly occur in the lamina lucida. Some of the antigens will be located in the epidermal side (roof) of the artificial split, while other antigens will be located at the dermal side (floor) of the artificial split. The substrate can be used for detection of circulating autoantibodies in pemphigoid diseases and further subtyping of antigen specificity of autoantibodies.  Ask permission and partaking by operating (plastic) surgeon.
Definitions and abbreviations
SSS
 Ask informed consent of patient undergoing routine surgery.
 Pick up the residue skin after surgery.
 Tighten up the skin on a silicone half sphere with needles or pins  Take skin punch biopsies of 6mm.
 Put the biopsies in a plastic transport tube filled with saline solution, maximum of 6 biopsies in 5mL tube.
 Rotate the tubes at room temperature with a rotary shaker.
 Take 
Quality check
New prepared human SSS substrate must be checked by staining with predetermined positive and negative control serum.
